Tong-Young Lee, PhD（李冬陽博士）
Founder and CEO, Celtec Inc.
Dr. Tong-Young Lee will be giving a special talk together with Ms. Amy Huang (General Manager of OBI Pharma, Inc.) on Aug. 5 (Sat.) 5:15 pm – 6:15 pm, Room B103, to share their personal experiences and stories.
Dr. Lee is the CEO and Founder of Celtec Inc. which is a start-up company and focus on developing novel cellular immunotherapies based on next generation technology – universal linker platform. Their goal is to revolutionize medicine by re-engaging the body’s immune system to treat cancer. Before Dr. Lee founded Celtec, he was the Vice President at Synovel Biosciences Inc. Synovel is using its proprietary class of drugs called ImmuEdit Aptamer TM to target several highly potential immune checkpoint drug targets for cancer treatment. In the meanwhile, he also served as a director at Fountain Biopharma Inc. which is an antibody drug discovery biotech company. Dr. Lee generated a largest fully-human antibody library and developed a first anti-IL6 monoclonal antibody in Asia Pacific area based on this technology platform. This project has gotten NT 40M government funding support. It is in preclinical stage and will get into human clinical trial in 2017. He is both inventor and project leader of this drug candidate. Before Dr. Lee joined Fountain Biopharma, he was working with late Dr. Judah Folkman at Harvard Medical School. Judah Folkman, M.D. (1933-2008), known as the father of angiogenesis research. Three angiogenesis inhibitors, bevacizumab (Avastin), ranibizumab (Lucentis) and ranibizumab (Eylea) were the first to be approved by the U.S. Food and Drug Administration and are now playing a major role in treatment.
About Celtec Inc. 震泰生醫
Celtec is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everything Celtec does, from early discovery to product development. Celtec focuses on developing novel therapeutic products that harness a patient’s own immune system to target and kill cancer cells. Celtec has two core technologies including fully-human scFv system and universal linker platform for next generation of cellular immunotherapies. Those novel strategies of immune cell therapy have the potential to be more effective and less long-term side effects regardless of the type of current treatments. Moreover, Celtec provides a universal, cost-effective, and easy process cutting-edge technology for cancer therapy.